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osting by EAbstract Background: Hepatitis A virus (HAV) infection is endemic in Egypt. Haemophiliacs are
at risk of transmission through exposure to blood products. We evaluated the seroprevalence of
hepatitis A in Egyptian patients with haemophilia A as well as the safety and immunogenicity of
subcutaneous hepatitis A vaccine in haemophiliacs.
Methods: 182 male children and adolescents were studied (82 patients with moderate and severe
haemophilia A and 100 healthy controls). Screening for anti-HAV antibody was done and seroneg-
ative subjects received hepatitis A vaccine (Havrix) at a dose of 720 Elisa Units at 0 and 6 months,
given subcutaneously in haemophiliacs and intramuscularly for controls. Seroconversion was
assessed 2 months after the second vaccine dose by anti-HAV IgG.
Results: Seroprevalence of HAV antibodies was 87.6% among haemophiliacs and 90% among the
control group. Seronegative children (mean age 4.4 ± 3.71 years) were signiﬁcantly younger than
seropositive children (mean age 10.2 ± 3.86 years). Hepatitis A vaccine was given to 10 non
immune haemophilia patients and 10 controls. The vaccine was well tolerated with local side effects
including pain in 40% and erythema in 20% of haemophiliacs versus 20% for pain and erythema in
the control group. All patients and controls developed seroconversion 2 months after the secondhmed Amin Street, St Fatima
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94 A.A.G. Tantawy et al.dose; with no signiﬁcant difference as regards the titre of anti-HAV IgG (351.4 ± 65.0 IU/L for
haemophiliacs and 367.0 ± 132.3 IU/L for controls).
Conclusion: HAV infection occurs early in life in Egyptian children, necessitating hepatitis A vac-
cination in early life. The vaccine is safe and effective when given subcutaneous in haemophiliacs
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Infection with hepatitis A virus (HAV) occurs worldwide and
is the most common cause of acute viral hepatitis [1]. The high-
est prevalence of this infection is seen in developing countries,
where low standards of sanitation promote the transmission of
the virus [2].
Patients with haemophilia require long-life intravenous infu-
sionof factor concentrates to treat bleedings,which increases the
risk of transmission of blood-borne infections mainly human
immunodeﬁciency virus (HIV) and hepatitis C virus (HCV)
[3]. Although transmission of HAV infection is primarily via
the faecal-oral route, transmissionmay also occur in individuals
with haemophilia through clotting factor concentrate, particu-
larly products inactivated by solvent–detergent puriﬁcation [4].
Egypt has the highest prevalence of antibodies to hepatitis C
virus (HCV) in the world, estimated nationally at 14.7% [5], it is
also classiﬁed as hepatitis A virus endemic country [6]. Acute
hepatitis A virus (HAV) super infection on the top of chronic li-
ver disease causes progressive disease, acute hepatic failure and
higher fatality rates, speciﬁcally in chronic hepatitis B (HBV)
and chronic hepatitis C virus (HCV) infections [7,8]. Both the
American Academy of Pediatrics (AAP) [9] and the Centres
for Disease Control (CDC) [10] recommend hepatitis A virus
(HAV) vaccine for persons with clotting-function disorders.
Hepatitis A vaccines licensed in the United States and used
in Egypt, including Havrix, are inactivated whole-cell virus
vaccines grown in human diploid ﬁbroblast cells [11]. The rec-
ommended route of administration for the vaccine is intramus-
cular with the potential risk of bleeding in patients with
congenital bleeding disorders especially in severe deﬁciencies
and in the presence of inhibitors [12,13]. A previous study re-
vealed that proper factor replacement in haemophilia patients
in Egypt is lacking [14] increasing their risk of bleeding with
intramuscular vaccination.
This study aimed to evaluate the seroprevalence of hepatitis
A virus infection in Egyptian children and adolescents with
moderate/severe haemophilia A compared to the general pop-
ulation, and to assess the efﬁcacy and safety of subcutaneous
hepatitis A vaccination in haemophiliacs.
2. Patients and methods
The study had a two-step design. The ﬁrst step was a cross sec-
tional study to determine the proportion of Egyptian children
and adolescents with moderate and severe haemophilia A who
had HAV protective antibody, compared to healthy age and
sex matched control group. Children who had no HAV protec-
tive antibody received two doses of HAV vaccine in the second
step, given subcutaneous in haemophiliacs and intramuscular
in healthy controls.
The study was conducted in the Paediatric Haematology
Unit, Children’s Hospital, Ain Shams University, in Cairo,Egypt, in the period from January 2009 to May 2010. The
study included 182 male children and adolescents, aged 2–
18 years. They were divided into two groups: 82 patients with
moderate/severe haemophilia A (mean age 9.49 ± 4.26 years)
and 100 healthy controls (mean age 8.67 ± 3.97 years). The
diagnosis of haemophilia A and severity were based on factor
VIII level assays [15]. Exclusion criteria included infants aged
less than two years, patients with a known immunologic de-
fect, HIV positive patients and patients with history suggestive
of previous hepatitis infection or previous vaccination with
hepatitis A vaccine.
The study was approved by the Ethical Committee of the
Paediatric Department, Ain Shams University. All patients
and/or their guardians signed informed consent forms.
All the included children and adolescents were subjected to
complete history taking including age, type and severity of
haemophilia, type of treatment received, age at ﬁrst factor VIII
infusion, and history suggestive of hepatitis infection (jaun-
dice, changing colour of urine, isolation in fever hospital, vom-
iting, previous abnormal liver function tests). Children were
given a thorough medical examination to exclude the presence
of any current liver disease.
Blood samples were obtained at enrollment from all chil-
dren to measure total HAV antibody level by competitive en-
zyme immunoassay test (ELISA) using commercially available
kits (DiaPro Diagnostic Bioprobes Srl., Milan, Italy). Initially
all patients were also tested for factor VIII-inhibitory activity
by a quantitative Bethesda method [16].
Children who had no HAV protective antibody, deﬁned as
anti-HAV antibody <20 mIU/mL [17], were given two 0.5 mL
doses of 720 ELISA (enzyme linked immunosorbent assay)
units of inactivated HAV vaccine, Havrix (Glaxo Smith-
Kline, Marly-Le-Roi, France) 6 months apart. Haemophilia
patients received the vaccine subcutaneously; while non-
haemophilic controls received the vaccine intramuscularly in
the deltoid. No pre-vaccination FVIII replacement therapy
was given to haemophilia patients. After vaccination all partic-
ipants were asked to record any local or systemic adverse
events for 3 days after each inoculation.
All vaccinated patients and controls had blood drawn
2 months after the second vaccine dose (month 8) to assess to-
tal HAV antibody by ELISA kits (DiaPro Diagnostic Biop-
robes Srl., Milan, Italy). Assessment of HAV IgM was done
by Enzyme Immuno Assay kits (DiaPro Diagnostic Bioprobes
Milano, Italy) one month after the 1st and 2nd vaccination
doses (at month 1 and 7) to exclude concurrent active HAV
infection.
3. Statistical analysis
Statistical analysis was done using SPSS software version 15.
Descriptive statistics were presented as means, standard devia-
tion (SD), number and percentage (frequency distributions).
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groups. The Fisher exact test was performed in tables contain-
ing values less than ﬁve. Student’s t-test was used to assess the
statistical signiﬁcance of the difference between two popula-
tion means in a study involving independent samples. The level
p< 0.05 was considered the cut-off value for signiﬁcance.
4. Results
This study included 182 male children and adolescents classi-
ﬁed into two age groups: 2–6 years (28.6%) and >6–18 years
(71.4%) (Table 1).
Among the studied children and adolescents, HAV seropos-
itivity was 87.8% in the haemophilia patients and 90% in
healthy controls with an overall prevalence of 89%, with nonTable 1 Age distribution of the studied groups of haemophiliac ch
Age Group Patients (n= 82) Co
No % No
2–6 years 20 24.4 32
>6–18 years 62 75.6 68
* Fisher exact test (two-tailed).
Table 2 Seroprevalence of anti-hepatitis A virus (anti-HAV) antibo
Variable Haemophilia Co
(n= 82) (n=
No % No
Anti-HAV negative 10 12.2 10
Anti-HAV positive 72 87.8 90
* Fisher exact test (two-tailed).
Table 3 Classiﬁcation of the studied haemophilic children as regar
Haemophilia severity HAV antibody seroprevalence
Negative
No %
Severe* 4 9.3
Moderate** 6 15.4
* Factor VIII level <1%.
** Factor VIII level 1–5%.
*** Fisher exact test (two-tailed).
Table 4 Seroprevalence of anti-hepatitis A virus antibodies (anti-
controls.
Age (years) Anti-HAV Ab negative An
(n= 20) (n
No % N
2–6 years 16 80 3
>6–18 years 4 20 12
* Fisher exact test (two-tailed).signiﬁcant difference between patients and control group
(Table 2). The seroprevalence of HAV was 90.7% and
84.6% in severe and moderate haemophilia, respectively, the
difference was not signiﬁcant (Table 3).
In our work we found that unvaccinated children (patients
and controls) who were seronegative for HAV were signiﬁ-
cantly younger than seropositive children (Table 4). The mean
age of seronegative children was 4.4 ± 3.71 years compared to
10.2 ± 3.86 years in seropositive children (p< 0.01).
Ten seronegative haemophilia patients received Havrix
vaccine subcutaneously while the 10 seronegative controls re-
ceived the vaccine intramuscularly at 0 and 6 months. The vac-
cine was well tolerated with minor local adverse events. Pain/
or soreness was the most common local non serious event in
both patients and controls (occurring in 40% and 20% of bothildren and control group.
ntrols (n= 100) Total P value*
%
32 52 0.323
68 130
dies among patients with haemophilia and control group.
ntrol Total P value*
100) (n= 182)
% No %
10 20 11 0.634
90 162 89
ds severity of haemophilia and hepatitis A virus seroprevalence.
P value***
Positive Total
No %
39 90.7 43 0.507
33 84.6 39
HAV Ab) in different age groups of the studied patients and
ti-HAV Ab positive Total P value*
= 162)
o %
6 22.2 52 <0.0001
6 77.8 130
Table 5 Comparison between patients with haemophilia and control group as regards total HAV antibody titre 2 months after 2nd
dose of Havrix.
Haemophiliacs (n= 10) Controls (n= 10) t P
Range Mean SD Range Mean SD
Anti-HAV titre in (mIU/ml) 275–450 351.4 65.0 175–525 367.0 132.3 0.335 0.742
95% conﬁdence interval (113.5 to 82.3).
96 A.A.G. Tantawy et al.groups, respectively), followed by erythema (occurring in 20%
of either group), no swelling or bruising was reported in pa-
tients or controls.
After subcutaneous injection of the hepatitis A vaccine, the
seroconversion rate two months after the second dose was
100%, similar to the results in the control group given intra-
muscular vaccine. As regards immunogenicity, there was no
statistically signiﬁcant difference between the mean titres of to-
tal anti-HAV antibody in haemophilia children compared to
control group (p> 0.05) (Table 5). No patients developed
anti-HAV IgM antibody or signs of acute hepatitis during
the study interval.
Among the studied 82 haemophilia patients, ﬁve patients
had FVIII inhibitors (6.1%), with titre varying between 2 an-
d4 BU/ml, considered as low titre [18], all had severe haemo-
philia and all were seropositive for HAV antibodies, so did
not receive the vaccine.5. Discussion
Hepatitis A virus infection is endemic in Egypt [6]. In this
study, HAV overall seroprevalence was 89% in children aged
2–18 years with no signiﬁcant difference between haemophili-
acs and controls. Previous studies [19,20], reported higher
HAV seroprevalence up to 100% in Egyptian children. An-
other Egyptian study in 2004 recorded a HAV prevalence of
86.2% in children aged 3–18 years [21]. A more recent study
[22] assessed the seroprevalence of HAV in 296 Egyptian chil-
dren aged 2.5–18 years of different social classes, and they
found that 61.4% were seropositive with a signiﬁcant increase
in seroprevalence (87.5%) in the low social class group. Simi-
larly, Salama et al. [23] described HAV seroprevalence of 50%
in high social class and 90% in low social class children in
Egypt. The high seroprevalence among our patients could be
related to the socioeconomic status as most of our studied pa-
tients belong to the unprivileged social class. The prevalence of
HAV infection is reported to closely correlate with environ-
mental sanitation and the prevailing socioeconomic and hygie-
nic conditions [24].
In our work we found that unvaccinated children (patients
and controls) who were seropositive for HAV were signiﬁ-
cantly older than seronegative children. This is presumably
due to increased likelihood of exposure to HAV with advanc-
ing age [22]. Similar age related increased HAV seroprevalence
has been reported in Egypt [21,25] and other HAV endemic
countries [26,27]. In Iran, Soﬁan et al. [28] reported HAV sero-
prevalence in Tehran rising from 51.7% in children aged 2–
5 years to 85% in the age group 16–20 years, while Kaya et
al. [29] reported the seroprevalence of HAV in an endemic area
in Turkey to vary from 19.2% in 2–5 years old children to
92.8% in 15–18 years old group.The possibility of HAV transmission via plasma derived
factor VIII concentrate is documented [30–32]. However in
the present study as well as in other studies [33], there was
no signiﬁcant difference between haemophiliacs and healthy
subjects regarding the seroprevalence of HAV, inspite of the
fact that haemophiliacs in our centre receive mainly on de-
mand plasma derived factor VIII products including cryopre-
cipitate and intermediate purity FVIII concentrate.
Presumably in the present study, the herd immunity conferred
by the poor sanitation has eliminated transfusion as a risk
factor.
In this study subcutaneous HAV vaccine was well tolerated
with minor local adverse events, similar to previous results
[7,31]. Soreness and erythema were the most common adverse
events in both patients and controls in our study, no swelling
or bruising was reported. However, Ragni et al. [32] reported
bruising and swelling occurring in 7% and 24%, respectively,
with no difference between haemophiliacs and controls.
As regards efﬁcacy after subcutaneous Havrix vaccine,
the present study showed 100% seroconversion rate two
months after the second dose, similar to control group given
the intramuscular vaccine. This is in agreement with Ragni
et al. [32] who found that the anti-HAV IgG titres peaked at
eight months, with 100% seroconversion rate.
As regards vaccine immunogenicity, there was no statisti-
cally signiﬁcant difference between the mean titres of anti-
HAV in haemophilia children compared to the control group.
This is in agreement with Zuckerman et al. [13] who compared
the immunogenicity, reactogenicity and safety of an inacti-
vated hepatitis A vaccine administered subcutaneously to pa-
tients with congenital coagulation disorders and found no
signiﬁcant difference in the geometric mean titres between
the two groups.
However, Ragni et al. [32] found that the HAV IgG geo-
metric mean titres were lower in the haemophilic children com-
pared to their non-haemophilic siblings. They suggested that
the potential reasons for these differences in HAV antibody ti-
tre may be the possibility that the immunogenicity of a vaccine
given by the subcutaneous route is inferior to that given by the
intramuscular route, which disagree with our results.
An important limitation of the study was the small number
of hepatitis A naive individuals in both haemophiliacs and
controls who were subjected to vaccination as well as the het-
erogeneity of route of vaccine administration of both groups.
In conclusion, these results show that the seroprevalence of
HAV infection in haemophiliacs in Egypt is similar to that in
the general population and there is no signiﬁcant excess of
HAV infections among haemophiliacs with high exposure to
coagulation factor concentrates in spite of high HAV endemic-
ity. Although the WHO postulated that in countries with high
HAV endemicity large-scale vaccination programmes are not
recommended [34], vaccination of high risk groups like haemo-
Hepatitis A virus in Egyptian patients with haemophilia 97philia is mandatory and prevaccination testing for antibodies is
recommended and cost-effective. Subcutaneous hepatitis A
vaccine given as standard two doses 6 months apart is recom-
mended in children as it is safe and immunogenic. Prevaccina-
tion factor replacement is generally not necessary with
subcutaneous vaccination.
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